Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis

March 25, 2015 updated by: Intersect ENT

A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

This study allows continued access to the Sinexus Intranasal Splint while a marketing application is being prepared. This study will generate additional performance, reimbursement and safety data for the steroid-eluting Sinexus Intranasal Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with chronic sinusitis (CS).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Fresno, California, United States
        • Central California Ear, Nose Thraot

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient is 18 years of age or older
  • Patient has a diagnosis of chronic sinusitis
  • Patient has a clinical indication for and has consented to FESS
  • Patient CT scan confirms CS diagnosis within 6 months of procedure
  • CT sacn confirms presence of disease in ethmoid sinus(es)
  • Planned FESS includes unilateral or bilateral total ethmoidectomy

Exclusion Criteria:

  • Immune deficiency (IGG subclass deficiency or IGA deficiency)
  • Oral-steroid dependent COPD, asthma or other condition
  • Clinical evidence of acute bacterial sinusitis
  • History or diagnosis of glaucoma or ocular hypertension
  • Clinical evidence or suspicion of invasive fungal sinusitis
  • Evidence of disease or condition expected to compromise survival or ability to complete follow-up
  • Known history of allergy or intolerance to corticosteroids
  • History of insulin dependent diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sinexus Intranasal Splint
Patient receives a drug-coated intranasal splint
Device: Steroid-Eluting Sinexus Intranasal Splint
Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety as Determined by the Frequency of Serious Adverse Local Tissue Response (SALT)
Time Frame: 30 days
30 days
Device Placement Success Rate
Time Frame: At the time of procedure
A proportion where the numerator is the number of successful device placements and denominator is the number of attempted sinuses.
At the time of procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of Changes From Baseline in Intra-ocular Pressure and Lens Opacities
Time Frame: Baseline and 30 days
Ocular safety was characterized by assessing the frequency and severity of changes from baseline in intra-ocular pressure and lens opacities. No specific pass/fail criteria we specified.
Baseline and 30 days
Number of Sinuses With Significant Post-operative Adhesion Formation
Time Frame: 30 days
Adhesions were graded on a 5 point categorical scale with grades 3 and 4 considered clinically significant. 0=none, 1=small/non-obstructing, 2=obstructing/easily separated, 3=dense/obstructing/difficult to separate, and 4=severe/complete adhesion to lateral nasal wall.
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Intersect ENT

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2009

Primary Completion (Actual)

June 1, 2009

Study Completion (Actual)

December 1, 2009

Study Registration Dates

First Submitted

June 1, 2009

First Submitted That Met QC Criteria

June 2, 2009

First Posted (Estimate)

June 3, 2009

Study Record Updates

Last Update Posted (Estimate)

April 20, 2015

Last Update Submitted That Met QC Criteria

March 25, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P500-0209

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Sinusitis

Clinical Trials on Steroid-Eluting Sinexus Intranasal Splint

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe